Senti Biosciences Holdings Inc

Senti Biosciences operates with a market capitalization of $32.39 million and a price-to-book ratio of 0.73, indicating that the company is trading at a discount to its book value. The company's liquidity position is characterized by a current ratio of 4.89, suggesting strong short-term liquidity, supported by $15.86 million in cash and equivalents. However, the company reported negative operating cash flow of $20.03 million and free cash flow of $10.20 million, reflecting ongoing operational cash outflows.

Profitability metrics show that Senti Biosciences is currently unprofitable, with a net loss of $11.20 million and an operating loss of $13.36 million. The return on equity (ROE) is -25.38%, and the return on assets (ROA) is -12.89%, both significantly below the industry median for biotechnology firms. These metrics indicate that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit.

The company's revenue is currently reported at $0.00, and there is no disclosed segment or geographic breakdown of revenue. This lack of revenue suggests that the company is in the early stages of development and has not yet commercialized its products. The absence of revenue concentration data implies that the company's future success is highly dependent on the development and commercialization of its pipeline products.

Looking ahead, the company is expected to remain unprofitable in the near term, with no revenue reported in the current fiscal year. The outlook for the next fiscal year is not provided, but the company's ongoing losses and lack of revenue suggest a challenging path to profitability. The company's capital expenditures are minimal, with only $15,000 in capex reported, indicating that the company is not currently investing heavily in physical assets.

The risk assessment for Senti Biosciences indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's high cash burn rate and lack of revenue pose significant operational risks. The dilution potential is currently low, but the company may need to raise additional capital in the future, which could lead to share dilution. The company has not issued any recent equity, and there are no immediate signs of dilution pressure.

Recent events and filings do not indicate any major developments for Senti Biosciences. The company has not disclosed any significant partnerships, product launches, or clinical trial results. The lack of recent events suggests that the company is in the early stages of development and has not yet reached key milestones. The company's recent financial performance and lack of revenue highlight the need for continued investment and development to achieve commercial success.

There are no material changes, watcher signals, or cross-source signals to report for Senti Biosciences Holdings Inc (SNTI.O) based on the provided facts. The data indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying recent shifts in market sentiment or corporate activity. The company profile shows Senti Biosciences Holdings I has zero officers, zero analysts covering the stock, and no index memberships. While there are seven top holders identified, the absence of analyst coverage and index inclusion suggests limited institutional scrutiny or broad market integration at this stage. Cross-source signal data from June 24, 2026, through July 14, 2026, records zero dispatches per day with null sentiment values. This complete lack of news flow or sentiment data during this period reinforces the absence of any notable events or market reactions to synthesize. Consequently, no significant developments or implications can be derived from the current dataset. Investors should note that the lack of analyst estimates, financial highlights, or recent news activity limits the ability to assess recent performance or outlook changes for SNTI.O.

Cash conversion of 1.79 ranks best-in-class against the biotechnology cohort median of 0.87, indicating superior efficiency.

The company maintains a low dilution risk profile, suggesting limited immediate threat to existing shareholder equity value.

Free cash flow burn improved to $49 million in FY2025, down from $92 million in FY2024, showing cost management.

Debt-to-equity ratio of 0.0 is above the cohort median, reflecting a conservative capital structure with minimal leverage.

Revenue collapsed to zero in FY2025, highlighting a complete lack of commercial product sales or recurring income streams.

The company posted a net loss of $52.8 million in FY2025, demonstrating an inability to achieve profitability.

Revenue CAGR of -10.4% over four years confirms a persistent downward trend in top-line growth performance.

Revenue $16.0k; Operating income +71,8% YoY.

• ▍Revenue $16.0k
• ▍Operating income +71,8% YoY
• ▍Operating margin -28850.0%

Revenue $22.0k; Operating income −15,3% YoY.

• ▍Revenue $22.0k
• ▍Operating income −15,3% YoY
• ▍Net income −2 271,6% YoY
• ▍Free cash flow −4 395,6% YoY
• ▍Net margin -65759.1%

Operating income −11,4% YoY; Net income +37,2% YoY.

• ▍Operating income −11,4% YoY
• ▍Net income +37,2% YoY
• ▍Free cash flow +38,3% YoY

Operating income −25,8% YoY; Net income −31,5% YoY.

• ▍Operating income −25,8% YoY
• ▍Net income −31,5% YoY
• ▍Free cash flow −37,4% YoY

Revenue $0.00; Operating income -$16.2M.

• ▍Revenue $0.00
• ▍Operating income -$16.2M

Revenue $22.0k; Operating income −12,7% YoY.

• ▍Revenue $22.0k
• ▍Operating income −12,7% YoY
• ▍Net income −16,4% YoY
• ▍Free cash flow −18,4% YoY
• ▍Net margin -279263.6%

Revenue $0.00, −100,0% YoY; Operating income +34,2% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +34,2% YoY
• ▍Net income +25,7% YoY
• ▍Free cash flow +46,7% YoY

Revenue $2.6M, −40,2% YoY; Operating income −52,5% YoY.

• ▍Revenue $2.6M, −40,2% YoY
• ▍Operating income −52,5% YoY
• ▍Net income −22,1% YoY
• ▍Free cash flow −2,5% YoY
• ▍Net margin -2774.6%

Revenue $4.3M, +55,2% YoY; Operating income −50,2% YoY.

• ▍Revenue $4.3M, +55,2% YoY
• ▍Operating income −50,2% YoY
• ▍Net income −5,2% YoY
• ▍Free cash flow −49,2% YoY
• ▍Net margin -1358.1%